Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
PTGX Insider Transactions (Form 4)
101
37 Form 4 filings on record, the earliest from Nov 19, 2024, newest first. Filing history page 1 of 2.
Protagonist Therapeutics, Inc (PTGX) had 3 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for PTGX runs to 37 Form 4 filings, the earliest from 2024-11-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying PTGX stock?
No insider purchases of PTGX were filed in the last 90 days.
How many insiders are selling PTGX stock?
4 insider sales of PTGX were filed in the last 90 days, totaling $16.92M.
Where can I see PTGX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page tracks PTGX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow PTGX insider buys?
Create a free InsiderAlpha account and press Watch on this page to add PTGX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
